financetom
Business
financetom
/
Business
/
OpenAI's annualized revenue hits $10 billion, up from $5.5 billion in December 2024
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
OpenAI's annualized revenue hits $10 billion, up from $5.5 billion in December 2024
Jun 9, 2025 12:53 PM

(Reuters) -OpenAI said on Monday that its annualized revenue run rate surged to $10 billion as of June, positioning the company to hit its full-year target amid booming AI adoption.

Its projected annual revenue figure based on current revenue data, which was about $5.5 billion in December 2024, has demonstrated strong growth as the adoption and use of its popular ChatGPT artificial-intelligence models continue to rise.

This means OpenAI is on track to achieve its revenue target of $12.7 billion in 2025, which it had shared with investors earlier. 

The $10 billion figure excludes licensing revenue from OpenAI-backer Microsoft ( MSFT ) and large one-time deals, an OpenAI spokesperson confirmed. The details were first reported by CNBC.

Considering the startup lost about $5 billion last year, OpenAI's revenue milestone shows how far ahead the company is in revenue scale compared to its competitors, which are also benefiting from growing AI adoption.

Anthropic recently crossed $3 billion in annualized revenue on booming demand from code-gen startups using its models.  

OpenAI said in March it would raise up to $40 billion in a new funding round led by SoftBank Group, at a $300 billion valuation.

In more than two years since it rolled out its ChatGPT chatbot, the company has introduced a bevy of subscription offerings for consumers as well as businesses.

OpenAI had 500 million weekly active users as of the end of this March.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Exclusive-Global health funds push for more private money, fearing government retreat
Exclusive-Global health funds push for more private money, fearing government retreat
Jan 22, 2025
LONDON (Reuters) - One of the world's biggest global health funders will ask the private sector for a steep increase in donations as concern of a shortfall in government contributions grows following a U.S. decision to exit the World Health Organization.     The Global Fund to Fight AIDS, Tuberculosis and Malaria told Reuters it will ask for almost 50% more money...
Hyundai Steel actively considering building US plant
Hyundai Steel actively considering building US plant
Jan 22, 2025
SEOUL, Jan 22 (Reuters) - South Korea's Hyundai Steel , an affiliate of automakers Hyundai Motor ( HYMTF ) and Kia, said on Wednesday it is actively considering building a steel plant in the United States. The move comes at a time when U.S. President Donald Trump is expected to step up protectionist trade policies, including potentially imposing 25% tariffs...
C3.ai Partners With McKinsey to Accelerate Enterprise AI Transformations
C3.ai Partners With McKinsey to Accelerate Enterprise AI Transformations
Jan 22, 2025
03:54 AM EST, 01/22/2025 (MT Newswires) -- C3.ai ( AI ) said late Tuesday it partnered with McKinsey & Company to help clients across industries speed up their Enterprise AI transformations. The company said the partnership combines McKinsey's AI expertise through its QuantumBlack unit with C3.ai's ( AI ) advanced Enterprise AI software to drive operational improvements. It added that...
ArriVent BioPharma Enters Licensing Deal With Lepu Biopharma for Gastrointestinal Cancer Drug
ArriVent BioPharma Enters Licensing Deal With Lepu Biopharma for Gastrointestinal Cancer Drug
Jan 22, 2025
03:46 AM EST, 01/22/2025 (MT Newswires) -- ArriVent BioPharma ( AVBP ) said late Tuesday it has entered into an exclusive licensing agreement with Lepu Biopharma to develop and commercialize gastrointestinal cancer drug MRG007 outside of Greater China. Under the terms of the deal, Lepu Biopharma will get an upfront payment and near-term milestone payments totaling $47 million in cash...
Copyright 2023-2026 - www.financetom.com All Rights Reserved